How Will the Tenosynovitis Drugs Market Grow? Key Trends and Opportunities for 2025 and Beyond
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What key factors are powering the surge in the market right now?
The market for drugs treating tenosynovitis has witnessed robust growth in recent times. It is projected to expand from $1.19 billion in 2024 to $1.29 billion in 2025, translating into a compound annual growth rate (CAGR) of 8.3%. The noteworthy growth in the preceding period can be ascribed to the escalating number of sports-related injuries, an upward trend in the older population, increased healthcare spending, better understanding of tenosynovitis, and a greater adoption rate of biologic treatment modalities.
How fast Is the market expected to grow, and what’s its future value?
In the coming years, there is expected strong expansion in the size of the tenosynovitis drugs market. The market is predicted to increase to $1.75 billion in 2029 with an 8.0% compound annual growth rate (CAGR). The growth predicted for this period can be attributed to factors like the rise of telehealth services, enlargement of global health initiatives, increasing incidence of musculoskeletal disorders, high demand for tenosynovitis drugs, and the growing occurrence of chronic diseases. Important trends for the forecast period encompass developments in surgical procedures, the use of robotics in surgery, progress in minimally invasive operations, advancements in nanotechnology, and the introduction of innovation in drug formulation.
Get your market report here!
https://www.thebusinessresearchcompany.com/report/tenosynovitis-drugs-global-market-report
Which key drivers are propelling the market’s growth?
The expansion of the tenosynovitis drugs market is anticipated due to the rising prevalence of musculoskeletal disorders. These disorders, which involve injuries to the muscles, tendons, ligaments, nerves, or joints, result in impaired movement and discomfort. Increase in sedentary lifestyle, work hazards, and aging populations are contributing to the high rates of musculoskeletal disorders. Anti-inflammatory medications and corticosteroids, used as tenosynovitis drugs, are administered to mitigate inflammation and pain associated with such conditions. For example, the UK-based Office for Health Improvement and Disparities reported in March 2023 that the percentage of individuals over 16 years with musculoskeletal conditions like arthritis or ongoing back or joint problems increased from 17.0% in 2021 to 17.6% in 2022. This demonstrates how the escalating instances of musculoskeletal conditions are propelling the tenosynovitis drugs market. Another factor fueling the growth of the tenosynovitis drugs market is the rising number of sports-related injuries. These injuries, which are often sustained during athletic activities or exercise, can range from minor sprains or strains to more serious fractures and dislocations. Factors such as overuse, improper techniques, insufficient warm-up or stretching, or collisions with players or objects are often the cause of these injuries. The use of tenosynovitis drugs in the treatment of these injuries by reducing the inflammation of tendons and relieving pain aids in a quicker recovery and better mobility. For instance, according to the UK-based insurance intermediary firm, Howden Group Holdings Ltd, the severity of ankle injuries in the English Premier League increased by 170% between October 2022 and January 2023, post the FIFA World Cup Qatar 2022. Injuries to the calf/shin and hamstring spiked by 200% and 130% respectively. This highlights how the growing occurrences of sports injuries are propelling the tenosynovitis drugs market.
What are the key segments defining the market?
The tenosynovitis drugs market covered in this report is segmented –
1) By Drug Type: Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Corticosteroids, Antibiotics, Other Drug Types
2) By Indication: De Quervain Tenosynovitis, Stenosing Tenosynovitis, Trigger Finger, Other Indications
3) By Route Of Administration: Oral, Injectable, Topical
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Naproxen, Diclofenac, Celecoxib
2) By Corticosteroids: Prednisone, Methylprednisolone, Dexamethasone, Triamcinolone
3) By Antibiotics: Penicillins, Cephalosporins, Fluoroquinolones, Macrolides
4) By Other Drug Types: Disease-Modifying Anti-Rheumatic Drugs (DMARDs), Biologics, Analgesics
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21297&type=smp
Who are the key players steering the development of the market?
Major companies operating in the tenosynovitis drugs market are Pfizer Inc., Roche Holding AG, Bayer AG, Sanofi S.A., AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Endo International plc, Lupin Limited, Mallinckrodt Pharmaceuticals, Zydus Cadila Healthcare, AdvaCare Pharma.
What emerging trends are influencing the growth of the market?
Key players in the tenosynovitis drugs market are aiming their efforts towards improving drug formulations to enhance their effectiveness, reduce undesirable side effects, and increase patient compliance. Progressive drug formulations such as delayed and controlled-release technologies are being used to prolong therapeutic effects, cut back on the number of doses, and aid in reducing gastrointestinal irritation, thereby increasing patient comfort and adherence overall. As an illustrative example, ANI Pharmaceuticals Inc., a pharmaceutical corporation based in the U.S., reported in July 2024 that it had obtained approval from the U.S Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) and launched Naproxen delayed-release tablets, USP. This drug was presented as a generic alternative to the reference listed drug (RLD), EC-Naprosyn, offering the same therapeutic advantages but at a lower cost. The delayed-release formulation is aimed at providing prolonged pain relief and decreased gastric irritation, proving beneficial for treating inflammatory conditions like arthritis, tendonitis, and tenosynovitis.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21297
Which regions are most influential in expanding the market?
North America was the largest region in the tenosynovitis drugs market in 2024. The regions covered in the tenosynovitis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Neurotrophic Keratitis Treatment Global Market Report 2025
Optic Nerve Disorders Treatment Global Market Report 2025
Nerve Repair And Regenerative Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/nerve-repair-and-regenerative-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
